21492-80-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-AMINO-PHENYL)-UREA is used as a chemical intermediate for the synthesis of pharmaceutical compounds due to its potential biological activities, including antiproliferative and antitumor effects. It serves as a building block for developing new drugs with therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical field, (4-AMINO-PHENYL)-UREA is used as a precursor in the synthesis of various agrochemicals, contributing to the development of pesticides, herbicides, and other agricultural chemicals that enhance crop protection and yield.
Used in Materials Science:
(4-AMINO-PHENYL)-UREA is utilized in materials science for the development of novel materials with specific properties. Its unique structure allows it to be incorporated into the synthesis of polymers, coatings, and other materials with tailored characteristics for various applications.
Overall, (4-AMINO-PHENYL)-UREA exhibits a broad spectrum of potential uses across different industries, making it a valuable compound for research and development efforts.

InChI:InChI=1/C7H9N3O/c8-5-1-3-6(4-2-5)10-7(9)11/h1-4H,8H2,(H3,9,10,11)

Upstream product

• 861536-16-5 N-(4-aminophenyl)cyanamide 
• 7647-01-0 hydrogenchloride 
• 106-50-3 1,4-phenylenediamine 
• 917-61-3 sodium isocyanate 

Downstream Products

• 88854-56-2 C₂₂H₂₄N₆O₆ 
• 1366233-11-5 C₂₃H₂₅N₃O₄ 
• 677752-90-8 4-{4-[2-(4-ureido-phenylamino)-pyrimidin-4-yl]-benzenesulfonyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 860574-46-5 (4-cyanoamino-phenyl)-urea 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

Mitomycin analogs

Novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula IIIa, STR1 wherein: Y is hydrogen or lower alkyl; and Z is an hydroxy substitited 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, or a 1-piperazinyl radical or an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, sulfamyl, or lower alkyl substituted anilino radical, or a radical of the formula, STR2 wherein R is hydrogen or lower alkyl and R1 is a nitrogen containing heterocyclic radical selected from the group consisting of amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R1 is a substituted lower alkyl radical selected from the group consisting of amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, piperazinyl lower alkyl, and pyridyl ethyl.